ISDA

Deposition Date 2011-08-03

Release Date 2011-10-12

Last Version Date 2024-10-30

Entry Detail

PDB ID:

3T9T

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Crystal structure of BTK mutant (F435T,K596R) complexed with Imidazo[1,5-a]quinoxaline

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.65 Å

R-Value Free:

0.20

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase ITK/TSK
Gene (Uniprot):ITK
Mutations:F435T,K596R
Chain IDs:A
Chain Length:267
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q08881 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

GOL

IAQ

Primary Citation

Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.

Kim, K.H, Maderna, A, Schnute, M.E, Hegen, M, Mohan, S, Miyashiro, J, Lin, L, Li, E, Keegan, S, Lussier, J, Wrocklage, C, Nickerson-Nutter, C.L, Wittwer, A.J, Soutter, H, Caspers, N, Han, S, Kurumbail, R, Dunussi-Joannopoulos, K, Douhan, J, Wissner, A.Show

Bioorg.Med.Chem.Lett. 21 6258 6263 (2011)

PMID: 21958547 DOI: 10.1016/j.bmcl.2011.09.008

Abstact

Imidazo[1,5-a]quinoxalines were synthesized that function as irreversible Bruton's tyrosine kinase (BTK) inhibitors. The syntheses and SAR of this series of compounds are presented as well as the X-ray crystal structure of the lead compound 36 in complex with a gate-keeper variant of ITK enzyme. The lead compound showed good in vivo efficacy in preclinical RA models.

Legend

Protein

Chemical

Disease

Primary Citation of related structures